




A



B



C



D

**Supplementary Fig. 1.** Cardiovascular risk factors from the three cardiovascular outcome trials: (A) glycosylated hemoglobin, (B) systolic blood pressure, (C) body weight, and (D) heart rate. CI, confidence interval; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering Trial; GLP-1, glucagon-like peptide 1.